Get the Stockscreener App
4.24
1.68%
0.07
After Hours:
3.91
-0.33
-7.78%
Alvotech stock is traded at $4.24, with a volume of 636.96K.
It is up +1.68% in the last 24 hours and up +28.10% over the past month.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
See More
Previous Close:
$4.17
Open:
$4.23
24h Volume:
636.96K
Relative Volume:
1.12
Market Cap:
$1.32B
Revenue:
$563.46M
Net Income/Loss:
$27.92M
P/E Ratio:
43.98
EPS:
0.0964
Net Cash Flow:
$-146.33M
1W Performance:
+0.00%
1M Performance:
+28.10%
6M Performance:
-21.48%
1Y Performance:
-56.47%
1-Day Range:
$4.165
$4.34
1-Week Range:
$4.05
$4.59
52-Week Range:
$2.94
$9.94
Alvotech Stock (ALVO) Company Profile
Compare ALVO vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
4.24 | 1.30B | 563.46M | 27.92M | -146.33M | 0.0964 |
TAK
Takeda Pharmaceutical Co Adr
|
15.77 | 50.27B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.07 | 40.31B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.69 | 40.32B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.95 | 33.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.57 | 23.17B | 3.17B | 1.29B | 1.01B | 27.09 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Nov-04-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-14-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-14-25 | Initiated | UBS | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
Alvotech's $125M Gamble: Fueling a Biosimilar Pipeline Amidst Headwinds - BriefGlance
Jefferies (JEF) Involved in Alvotech's Share Issuance Suspension - GuruFocus
Alvotech (ALVO) launches shelf offering; concurrent EEA private placement indicated - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Alvotech initiates $125M fundraising via public and private offering for biosimilar growth - MSN
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares - The Manila Times
Alvotech (ALVO) terminates Jefferies ATM share prospectus - Stock Titan
Alvotech seeks $125M to fund biosimilar medicines via share sale - Stock Titan
Alvotech Stock (LU2557688560): Nordic-listed biosimilar player draws focus after latest trading move - AD HOC NEWS
Alvotech seeks FDA nod for Simponi, Eylea biosimilars again - Drug Store News
Why Alvotech (ALVO) Is Up 17.8% After FDA Advances Its Entyvio Biosimilar AVT16 Application - simplywall.st
Alvotech hits critical inflection as biosimilar pipeline nears FDA decisions - MSN
Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock? - The Motley Fool
Alvotech shares jump after FDA accepts Entyvio biosimilar application for review (ALVO) - MSN
Alvotech gains on FDA acceptance of Entyvio biosimilar BLA - MSN
Alvotech allocates shares to a board director as part of his pay package, filed with Luxembourg regulator. - Pluang
Transactions of Managers and Closely Associated Persons - Stock Titan
Alvotech Hits Critical Inflection as Biosimilar Pipeline Nears FDA Decisions - MarketBeat
Transcript : Alvotech Presents at UBS Virtual Generics and Biosimilars Day, Jun-10-2026 10 - marketscreener.com
Alvotech seeks US nod for biosimilars to J&J’s Simponi and Regeneron’s Eylea again - MSN
ALVO: Poised for rapid biosimilar expansion, targeting key launches and market leadership by 2027 - TradingView
Alvotech (ALVO) Returns To Quarterly Profitability Challenging Concern Over Persistent Losses - simplywall.st
Alvotech resubmits BLA for proposed Eylea biosimilar - Eyes On Eyecare
Alvotech Takes The Lead On Vedolizumab - Citeline News & Insights
Assessing Alvotech (ALVO) Valuation After FDA Acceptance Of AVT16 Biosimilar Application - simplywall.st
Top Biotech Gainers: TNGX Hits New High, ALVO Moves Closer To FDA Approval, ZVRA, IDYA Turn Heads - RTTNews
Alvotech (ALVO) Secures FDA Review for New Biosimilar AVT16 - GuruFocus
Alvotech (NASDAQ: ALVO) Q1 2026 results and FDA review of key biosimilars - Stock Titan
FDA to review biosimilar of Entyvio - Managed Healthcare Executive
Biggest stock movers Monday: NRIX, INTC, and more (NASDAQ:NRIX) - Seeking Alpha
ALVO: Accelerated U.S. biosimilar launches and global expansion drive strong growth outlook - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Alvotech announces FDA acceptance of BLA for AVT16 biosimilar - grafa.com
Alvotech: Speculative 'Buy' Despite The FDA's CMC Requirements (NASDAQ:ALVO) - Seeking Alpha
US FDA Accepts Alvotech's Biologics License Application for Entyvio Biosimilar - Moomoo
Alvotech stock surges on FDA review of Entyvio biosimilar By Investing.com - Investing.com Canada
Why is Alvotech stock rallying today? - Investing.com UK
FDA accepts Alvotech's application for AVT16, a... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Why is Alvotech stock rallying today? By Investing.com - Investing.com Nigeria
Alvotech stock surges on FDA review of Entyvio biosimilar - Investing.com
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
9.24%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):